Introduction: YKL-40 is a glycoprotein that plays role in inflammation and malignant processes. High serum YKL-40 levels are associated with short survive in cancer and chronic obstructive pulmonary disease (COPD) is another reason to increase its' level. However, limited knowledges are known in YKL-40 along with lung cancer and COPD.
INtroduCtIoN
In cancer treatments new therapy options are needed to be developed to improve survive. Recently some biomarkers were discussed whether they can allow new treatment modalities in cancer like agents against growth factors and their receptors (1) . YKL-40 is a newly defined marker expressed by both malignant and non-malignant cell has role in tumour and inflammatory processes. Several solid tumour cells produce YKL-40 such as breast, colon, lung, kidney, prostate. Myelocyte series, chondrocytes and fibroblasts secrete YKL-40 as non-malignant cells causing increased serum YKL-40 levels during inflammatory process (2) . However its function in malignant process hadn't been shown with in vivo studies yet, YKL-40 may play role in proliferation, differantiation, angiogenesis and inhibition of apoptosis. According to twenty retrospective studies, serum YKL-40 concentration is exactly 10 times higher than healthy group. There is no well-defined cut-off value because it depends on methodology of studies and types of malignancies. YKL-40 isn't a specific marker for a particular cancer but when we analyse twenty retrospective studies (2) . One prospective study about gliomas (overall 2543 patients) is suggestive for survival (3) . But depending on the current studies; some cancer cells don't secrete YKL-40. This indicates the variation of tumour cell biological behaviour. According to all these data's; we can't use YKL-40 for diagnosis or during follow up period in a specific kind of malignancy (2) .
In lung cancer, serum YKL-40 level is expected to be increased like other malignancies. Especially in advanced non-small cell lung cancer (nSCLC) high serum levels are associated with poor prognosis. In a study with 189 nSCLC (88% advanced stages) patients, cut-off value was calculated 209 ng/mL. Above this value surveys were extremely low (32 weeks versus 41 weeks). So it was a statistically significant prognostic factor in advanced nSCLC (4) . In an another study with 61 nSCLC patients' cut-off value was 165 ng/mL and survey analyses were statistically significant. (In high serum levels survey was seven months, in the low group survey was 18 months). Also this study revealed the correlation with performance status and YKL-40 level (5) . SCLC is less frequent type of lung cancer but extensive disease has a median survival duration of 6 months. There is no routinely used serological biomarker to detect SCLC earlier. Although it is not a specific biomarker, YKL-40 has been discussed in a study for SCLC with 131 patients. In extensive disease YKL-40 level was higher than limited disease. High serum YKL-40 level had been associated with poor prognosis within the 6 months after starting the chemotherapy (6) . In this study we planned to evaluate YKL-40 level for all subtypes of lung cancer by considering all stages. Due to YKL-40 is important in inflammatory process, we have discussed results taking into account presence of choronic obstructive pulmonary disease (COPD).
MAterIALs and MetHods
One hundred patients with lung cancer were enrolled study (84 men, 16 women, median age of 62 years). Biopsy materials were obtained by bronchoscopic mucosal biopsy, trans bronchial lymph node aspiration, transthoracic fine needle aspiration or surgery. Blood samples were collected before any treatment. Time interval between the drawing of blood and centrifugation of blood stored at room temperature is less than 3 hours. Blood was spun at 3000 revolutions per minute for 10 minutes. Supernatant was placed into 2 cc eppendorf tubes after centrifugation and stored at -80°C deep-freezer.
Patients enrolled study between 2009-2011 and the median following time is 8.7 months. At the end of the study only 39% of patients was alive. Exclusion criterias were; age under 18 and previous cancer history. TnM staging was done according to International Association for the Study of Lung Cancer (IASLC)-7 th edition. Eastern Cooperative Oncology Group (ECOG) performance status, age, sex, smoking status (packet/ year), hemogram, biochemical parameters (LDH and calcium specifically discussed) and coexistence of COPD are recorded for each patient. Inoperable patients were given chemotherapy/radiotherapy according to treatment protocols.
We evaluate normal serum level of YKL-40 in 30 healthy adults (15 men, 15 women, median age 60 years). none of the participants in control group had a chronic disease that requires regular drug use or symptom of malignancies.
Study protocol was approved by ethical committee of university and all participants were informed about study design.
Procedure of detection of serum concentration of YKL-40 is based on enzyme-linked immunosorbent assay (ELİSA) (MicroVue ™ , YKL-40 EIA Summary, Quidel, San Diego, CA 92121, USA). Principle of procedure consists of three steps; a micro assay plate coated with streptavidin and a biotinylated murine monoclonal antibody to human YKL-40, an AP-conjugated rabbit polyclonal antibody to YKL-40, and a chromogenic substrate (1) (2) (3) . In third step an incubation period is needed and the colour intensity is measured spectrophotometically. All serums were studied duplicate to increase accuracy. This part of the study was done by a microbiologist who doesn't know the study's parameters and endpoints.
statistical Analysis
Frequency (percent) for categorical variables, mean ± standard deviation [median (minimum-maximum)] for metric variables was given as descriptive statistics. In order to compare two/more independent groups, Mann-Whitney U test/Kruskal-Wallis variance analysis for metric variables, chi-square test for categorical variables was used. Spearman correlation coefficient was used to assess the degree of association between two variables. The area under the ROC curve gives an estimate of the overall accuracy of YKL-40 level. An area of 0.50 implies that the variable adds no information. The area under the ROC curve and 95% confidence interval for YKL-40 level was calculated in the manner described by Hanley and Mcneil (7) . The sensitivity, specificity, positive and negative predicted values, likelihood ratios and overall accuracy were calculated for diagnostic performance of YKL-40 level. Overall survival was estimated by Kaplan-Meier survival analysis. The log-rank test was used to compare survival estimates between subgroups. p< 0.05 was considered as statistically significant.
resuLts
One hundred patients (16 female and 84 male) were enrolled to the study and results were compared to 30 healthy volunteers. Mean ages were 62 ± 8.2 in group of patients and 60.9 ± 10.3 in control group. There were no statistically significant differences between control and study group in terms of demographic characteristics. Fourty-two patients were in stage 4 at time of diagnosis. There were thirty-three operable patients but surgery was performed only twenty-six of them because of poor medical conditions. Eighty-seven of patients were diagnosed with nSCLC and most frequent cell type was squamous cell lung cancer. Patients were analysed by dividing into groups according to existence of COPD and comorbidity. Characteristics of patients were summarized in Table 1 .
serum YKL-40 Levels and Patient Characteristics
While the median serum YKL-40 level was 229.0 ± 110.7 ng/mL in patients, it was 144.5 ± 105.7 ng/mL in control group and it was statistically significant (p< 0.001). Serum YKL-40 level wasn't related to age, gender, performance status and histopathologic type of tumour (p> 0.05). In nSCLC group there was no association between YKL-40 and stage ( Table 2 ). In group of SCLC mean YKL-40 levels were similar between extended and limited disease (p> 0.05). Operability, histopathological type, tumour size and nodal status did not affect YKL-40 level. Existence of COPD (n= 42 patients) wasn't correlated with high level of YKL-40 (Table 3 ). Patients who have any of chronic diseases (hypertension, diabetes mellitus, renal disease, congestive heart failure and coronary artery disease) had higher serum YKL-40 levels than those without comorbidity (238.6 ± 105.4 ng/mL versus 218.5 ± 117.2 ng/ mL) ( Table 1) . 
serum YKL-40 Levels and survival
Survival was analysed for TnM staging, histopathologic type of tumour, operability and coexistence of COPD regardless of serum YKL-40 level. In nSCLC group, as the stage increased and tumour growed survival got lower. Similarly as the number of involvement lymph node increased, coexistence of COPD and inoperability were related to poor prognosis (p< 0.05). In terms of cell type patients diagnosed with SCLC had shorter survival than nSCLC patients (p= 0.019).
Survey was analysed according to three cut-off values of serum YKL-40 level, 133 ng/mL (high specifity and sensitivity), 159 ng/mL (high sensitivity) and 162 ng/mL (high specifity) ( Figure 1 ). There was no association between serum YKL-40 levels and other parameters described in Table 1 . Above all cut-off values survival was shorter (p> 0.05). The highest p value was found (p= 0.09) in limited disease in SCLC for 162 ng/mL. Although it had no significance, above all cut-off values inoperability was related to poor prognosis. Patients with COPD had shorter life expectancy according to 133 ng/mL (p= 0.01) ( Also by immunohistochemically staining they demonstrate alveolar macrophages are major cells to produce YKL-40 in lung tissue (9) . We didn't record patients' medications or stage of COPD, however, bronchodilators and theophylline can reduce inflammation hereby we detect YKL-40 level lower than expected in patients with COPD. Again, Letuve et al. presents increased serum YKL-40 levels in smoking patients compared to non-smokers (9) . Current study smoking frequency is 81%. So YKL-40 level is increased in smokers without COPD. Therefore, drugs especially working in inflammatory process should be considered when designing a study with serum YKL-40.
It has been investigated in several studies for different type of tumours. Eventually it was detected as a poor prognostic factor but it wasn't specific to any cell type. However, its biological function in malign process isn't well known yet it's suggested to take place in proliferation, differantiation, protecting tumour cells from apoptosis. But more in vivo studies are needed (10) . There are limited reports that YKL-40 is associated with survival in lung cancer. We followed patients for fifteen months and after this period 61 patients had been died. In our study we defined three cut-off values. Despite survival was shorter above all cut-off values it wasn't significant (p> 0.05). Because we had patients who diagnosed in early stages and most of study group was nSCLC; so this heterogeneity in patient distribution may be effective on results.
A study from Turkey designed with nSCLC patient serum YKL-40 level is higher in locally advanced/ advanced staged nSCLC (240.20 ng/mL (104.91-408.07) vs. 82.28 ng/mL (56.53-265.61)) (11). In contrast to this study, serum YKL-40 levels were slightly higher in operable groups than inoperable group. So it's suggestible that YKL-40 is released to serum from tumour cells since early stages or existence of an inflammatory disease changes result. If post-operative YKL-40 levels and effect of comorbidities had also been measured it would be easy to have a healthy comparison. Unfortunately, this the missing point of current study.
Although it was not statistically significant, serum YKL-40 level was higher in SCLC than nSCLC. But sample sizes were quite different between groups and only 13 of 100 patients were diagnosed SCLC. Both groups should be analysed again for an equal number of patients in each histological types.
There are limited reports that YKL-40 is associated with survival in lung cancer. We followed patients for fifteen months and after this period 61 patients had been died. In our study we defined three cut-off values. Despite survival was shorter above all cut-off values it wasn't significant (p> 0.05). Because we had patients who diagnosed in early stages and most of study group was nSCLC; so this heterogeneity in patient distribution may be effective on results.
In current study, existence of COPD was evaluated with YKL-40 in patients with lung cancer in respect of surviv- The role of YKL-40 in malign process is still unknown and very few studies have evaluated the functional role of YKL-40 expression in cancer cells. It has been suggested that playing roles in proliferation, differentiation and neovascularization of malignant cells, protects the cells from undergoing apoptosis. But also it's obviously defined that it has importance for inflammatory events like extracellular tissue remodelling, fibroblast activity, however there is not enough in vivo studies to prove yet. In literature YKL-40 is mentioned for both malignant and non-malignant diseases. So its' signalling pathways, molecular interactions, receptors and if present different molecular isoforms needed to be defined. After these questions are answered we can start to work on therapies targeting YKL-40.
In conclusion we have demonstrated that YKL-40 level is higher in patients with lung cancer than healthy people. But we couldn't define any prognostic value in lung cancer except for patients with COPD. To understand the biological function of serum YKL-40 in lung cancer, expression in tissue and correlation with serum level should be demonstrated. Then neutralizing antibodies targeted against YKL-40 can be an alternative treatment in lung cancer.
CoNCLusIoN
YKL-40 level is useful in lung cancer however it's not related to cell type and prognosis. Also co-morbidities that increase inflammation should be considered when analysing. Current study demonstrated that it is associated with poor prognosis in lung cancer patients with COPD, supporting that YKL-40 is a both tumour and inflammation related biomarker.
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